449 related articles for article (PubMed ID: 21075282)
21. Iron regulation by hepcidin.
Zhao N; Zhang AS; Enns CA
J Clin Invest; 2013 Jun; 123(6):2337-43. PubMed ID: 23722909
[TBL] [Abstract][Full Text] [Related]
22. Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of β-thalassemia.
Olivera J; Zhang V; Nemeth E; Ganz T
Blood Adv; 2023 Jul; 7(14):3339-3349. PubMed ID: 36995275
[TBL] [Abstract][Full Text] [Related]
23. The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia.
Rivella S
Blood Rev; 2012 Apr; 26 Suppl 1(0 1):S12-5. PubMed ID: 22631035
[TBL] [Abstract][Full Text] [Related]
24. Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model.
Artuso I; Lidonnici MR; Altamura S; Mandelli G; Pettinato M; Muckenthaler MU; Silvestri L; Ferrari G; Camaschella C; Nai A
Blood; 2018 Nov; 132(21):2286-2297. PubMed ID: 30209118
[TBL] [Abstract][Full Text] [Related]
25. Identification of erythroferrone as an erythroid regulator of iron metabolism.
Kautz L; Jung G; Valore EV; Rivella S; Nemeth E; Ganz T
Nat Genet; 2014 Jul; 46(7):678-84. PubMed ID: 24880340
[TBL] [Abstract][Full Text] [Related]
26. Erythropoietic regulators of iron metabolism.
Ganz T
Free Radic Biol Med; 2019 Mar; 133():69-74. PubMed ID: 29981834
[TBL] [Abstract][Full Text] [Related]
27. Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait.
Jones E; Pasricha SR; Allen A; Evans P; Fisher CA; Wray K; Premawardhena A; Bandara D; Perera A; Webster C; Sturges P; Olivieri NF; St Pierre T; Armitage AE; Porter JB; Weatherall DJ; Drakesmith H
Blood; 2015 Jan; 125(5):873-80. PubMed ID: 25519750
[TBL] [Abstract][Full Text] [Related]
28. Hepcidin biology and therapeutic applications.
Nemeth E
Expert Rev Hematol; 2010 Apr; 3(2):153-5. PubMed ID: 21083458
[TBL] [Abstract][Full Text] [Related]
29. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha.
Pinto JP; Ribeiro S; Pontes H; Thowfeequ S; Tosh D; Carvalho F; Porto G
Blood; 2008 Jun; 111(12):5727-33. PubMed ID: 18326822
[TBL] [Abstract][Full Text] [Related]
30. Imbalance of erythropoiesis and iron metabolism in patients with thalassemia.
Huang Y; Lei Y; Liu R; Liu J; Yang G; Xiang Z; Liang Y; Lai Y
Int J Med Sci; 2019; 16(2):302-310. PubMed ID: 30745811
[No Abstract] [Full Text] [Related]
31. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias.
Camaschella C; Nai A
Br J Haematol; 2016 Feb; 172(4):512-23. PubMed ID: 26491866
[TBL] [Abstract][Full Text] [Related]
32. Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult β-thalassemia major.
Casu C; Chessa R; Liu A; Gupta R; Drakesmith H; Fleming R; Ginzburg YZ; MacDonald B; Rivella S
Haematologica; 2020 Jul; 105(7):1835-1844. PubMed ID: 31582543
[TBL] [Abstract][Full Text] [Related]
33. Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia.
Origa R; Cazzola M; Mereu E; Danjou F; Barella S; Giagu N; Galanello R; Swinkels DW
Haematologica; 2015 May; 100(5):e169-71. PubMed ID: 25596269
[No Abstract] [Full Text] [Related]
34. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.
Manolova V; Nyffenegger N; Flace A; Altermatt P; Varol A; Doucerain C; Sundstrom H; Dürrenberger F
J Clin Invest; 2019 Dec; 130(1):491-506. PubMed ID: 31638596
[TBL] [Abstract][Full Text] [Related]
35. [Research progress of iron metabolism in phenotype modification of β-thalassemia].
Chen D; Sun X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Jan; 38(1):27-31. PubMed ID: 33423253
[TBL] [Abstract][Full Text] [Related]
36. Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia.
De Franceschi L; Daraio F; Filippini A; Carturan S; Muchitsch EM; Roetto A; Camaschella C
Haematologica; 2006 Oct; 91(10):1336-42. PubMed ID: 17018382
[TBL] [Abstract][Full Text] [Related]
37. The mutual control of iron and erythropoiesis.
Camaschella C; Pagani A; Nai A; Silvestri L
Int J Lab Hematol; 2016 May; 38 Suppl 1():20-6. PubMed ID: 27161430
[TBL] [Abstract][Full Text] [Related]
38. Transferrin is a major determinant of hepcidin expression in hypotransferrinemic mice.
Bartnikas TB; Andrews NC; Fleming MD
Blood; 2011 Jan; 117(2):630-7. PubMed ID: 20956801
[TBL] [Abstract][Full Text] [Related]
39. The molecular basis of iron overload disorders and iron-linked anemias.
Kaplan J; Ward DM; De Domenico I
Int J Hematol; 2011 Jan; 93(1):14-20. PubMed ID: 21210258
[TBL] [Abstract][Full Text] [Related]
40. Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development.
Porter J; Taher A; Viprakasit V; Kattamis A; Coates TD; Garbowski M; Dürrenberger F; Manolova V; Richard F; Cappellini MD
Expert Rev Hematol; 2021 Jul; 14(7):633-644. PubMed ID: 34324404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
